GlassScriptPhysician profile
Caroline Kozek
NPI 1912623265
$7,453.85
in general payments reported to CMS, 2019-2025
32 companies · $1,997 in 2025
The $1,997 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $124 · 2023: $1,761 · 2024: $3,572 · 2025: $1,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,796 · Consulting Fee: $1,403 · Honoraria: $632 · Education: $274 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,796.43 |
| Consulting Fee | $1,402.50 |
| Honoraria | $632.00 |
| Education | $273.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,674.40 | 2023-2025 | |
| Blueprint Medicines Corporation | $920.00 | 2023-2025 | Ayvakit |
| Incyte Corporation | $818.84 | 2023-2025 | Jakafi, Jakafi |
| Taiho Oncology, INC. | $547.66 | 2023-2025 | |
| Daiichi Sankyo INC. | $533.73 | 2023-2025 | Vanflyta, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $530.96 | 2023-2025 | Iclusig |
| Pharmaessentia USA Corporation | $494.85 | 2022-2025 | Besremi |
| E.R. Squibb & Sons, L.L.C. | $363.77 | 2023-2024 | Reblozyl |
| Abbvie INC. | $326.12 | 2024-2025 | |
| Glaxosmithkline, LLC. | $198.26 | 2024-2025 | Ojjaara |
| Geron Corporation | $189.90 | 2024-2025 | Rytelo |
| Janssen Biotech, INC. | $114.75 | 2025 | Rybrevant, Carvykti, Tecvayli |
| Astellas Pharma US INC | $94.69 | 2023-2025 | Xospata, Vyloy |
| Cti Biopharma Corp. | $85.31 | 2023 | Vonjo |
| Sobi, INC | $71.20 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $69.16 | 2025 | |
| Autolus INC | $66.46 | 2025 | |
| Adaptive Biotechnologies Corporation | $53.43 | 2024-2025 | Clonoseq |
| Pharmacosmos Therapeutics INC. | $41.00 | 2025 | Monoferric |
| Merck Sharp & Dohme LLC | $36.12 | 2023-2025 | Prevymis, Keytruda |
| Astrazeneca Pharmaceuticals LP | $32.11 | 2023 | Imfinzi |
| Rigel Pharmaceuticals, INC. | $21.97 | 2024 | Tavalisse, Rezlidhia |
| Stemline Therapeutics INC. | $21.14 | 2025 | Elzonris |
| Servier Pharmaceuticals LLC | $18.16 | 2025 | |
| Agios Pharmaceuticals, INC. | $17.95 | 2025 | Pyrukynd |
| Celgene Corporation | $17.81 | 2025 | Reblozyl |
| Azurity Pharmaceuticals, INC. | $17.46 | 2025 | Danziten |
| Beone Medicines USA, INC. | $16.43 | 2025 | Brukinsa |
| Genmab U.S., INC. | $16.31 | 2025 | Epkinly |
| Sanofi-Aventis U.S. LLC | $15.08 | 2024 | |
| Bard Peripheral Vascular, INC. | $14.91 | 2024 | Trek |
| Syndax Pharmaceuticals, INC. | $13.91 | 2025 | Niktimvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Kozek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.